



Ivan Montoya, M.P.H., M.D., Deputy Director

Division of Therapeutics and Medical Consequences (DTMC)

National Institute on Drug Abuse

Dr. Montoya is a psychiatrist and epidemiologist who specializes in the development of therapeutics for Substance Use Disorders (SUDs). He provides programmatic oversight for grants and contracts in DTMC, and manages activities and resources of the Division involved in the research of new therapeutics and the

medical consequences of SUDs. He also provides medical oversight to grants and contracts, as well as supports NIDA's implementation of NIH wide policies for the Clinical Trials Stewardship Initiative. He leads NIDA's marijuana medications development initiative and the recently published funding opportunity for the development of medications to prevent opioid use disorders and overdose, which is part of the NIH's Public Private Partnership to combat the opioid use crisis. He collaborates with the IRP in research projects, with NIDA's International Office in the Latin American Initiative, and is a member of several scientific interest workgroups. Previous experience includes seven years as a clinical investigator in the Intramural Research Program of NIDA, and four years in academia. He joined NIDA in December 1999.